MULTIPLEX+
The goal in modern diagnostics is to develop a reliable, accurate, cost-effective, quantitative, multiplex and rapid test, which precisely characterizes and profiles cancer. In Multiplex+, we combine visualization and sequencing methods to come up, in one single test, with a specific “barcode” of each cancer, suggesting the specific, personalized treatment and medicines to be used, but also the length of cancer therapy. In comparison of our Multiplex+ with conventional diagnostics and diagnostic technologies showing that our test scores positively in all aspects crucial for effective diagnostic test that is quantitative, cheap, rapid, adaptive, specific, multiplexed, simple, high-throughput, with preserved tissue morphology. Due to its advantages over conventional diagnostics, Multiplex+ has the greatest potential to become a very reliable and precise diagnostic tool in primary cancer diagnostics and the first choice for clinicians.
The diagnostic kits vDetect and rTest are based on an improved and re-designed Charité Berlin protocol also recommended by the WHO.
We offer custom, high quality synthesis of aptamers, siRNA, miRNA, antagomirs, qPCR probes, oligonucleotide triphosphates etc.
MDX small RNA sequencing products are compatible with Illumina sequencing technology and designed for the simplest, the most economical, the most precise and automated small RNA library preparation, enabling a great elimination of sequencing errors and biases.
MultiplexDX IP-based and innovative platform merges histopathology methods, biomarker quantification, visualization and gene expression with a single-cell resolution by combining our proprietary visual and sequencing technologies into one diagnostic test.
MultiplexDX offers a wide range of bioinformatics services, including genome assembly, gene expression, metagenomics analyses and data visualization.
